Browse Studies — Arctuva

Phase 1

Phase I/II Trial of Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Pros…

Head and Neck CancerHead and Neck Squamous Cell CarcinomaParanasal Sinus Neoplasms+9 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07667400

Observational

WVU011625: The Role of Scheduled Intravenous Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer

Patients undergoing concurrent chemoradiotherapy (CCRT) for head and neck squamous cell carcinoma frequently experience treatment-related toxicities including …

Squamous Cell Carcinoma of HypopharynxSquamous Cell Carcinoma of LarynxSquamous Cell Carcinoma of Oropharynx+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

West Virginia UniversityNCT07784855

Phase 1

Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors

The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through bl…

Solid TumorSmall Cell and Non-small Cell Lung CancerHead and Neck Cancer+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Rapa Therapeutics LLCNCT05144698